BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting To Review NurOwn Biologics License Application Scheduled For September 27, 2023
Portfolio Pulse from Benzinga Newsdesk
BrainStorm Cell Therapeutics announced an FDA Advisory Committee meeting scheduled for September 27, 2023, to review the Biologics License Application (BLA) for NurOwn, its investigational stem cell therapy for amyotrophic lateral sclerosis (ALS). The Prescription Drug User Fee Act (PDUFA) action date is targeted for December 8, 2023.
June 06, 2023 | 10:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BrainStorm's stock may be positively impacted by the FDA Advisory Committee meeting to review NurOwn's BLA for ALS treatment.
The FDA Advisory Committee meeting to review NurOwn's BLA is a significant milestone for BrainStorm. A positive outcome could lead to potential approval and commercialization of the therapy, which would benefit the company and its stock price. Investors may react positively to this news in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100